Transparency Market Research Report Added "Global Premenstrual Syndrome Market - Industry Analysis, Size, Share, Growth, Trends And Forecast 2014 - 2020" to its database.
Albany, NY -- (SBWIRE) -- 06/04/2015 -- Premenstrual syndrome (PMS) alternatively known as premenstrual tension is a combination of physical, emotional, psychological disturbances among women of child bearing age. Premenstrual syndrome symptom occurs 1-2 weeks before the onset of menstruation and usually disappears once the menstrual bleeding starts. The exact cause of the disease is though not clear yet fluctuations in hormone level are one of the prominent reasons for onset of symptoms.
Browse Full Report with TOC @ http://www.transparencymarketresearch.com/premenstrual-syndrome-market.html
Other associated cause of the disease include low level of vitamin and mineral level, high intake of salty food and frequent alcohol & caffeine consumption. Symptoms of the diseases include acne, swollen breasts, troubled sleeping, muscles pain, mood swings and anxiety disorders. A more severe form of PMS known as premenstrual dysphoric disorder, characterized by repeated transitory cyclic disorder along with increased level of anger, anxiety and tension as compared to PMS disease.
Approximately 20-30% of the menstruating women are believed to be affected by premenstrual syndrome of which 3-8% of them have premenstrual dysphoric disorder. Drugs that are usually employed as therapeutics include nonsteroidal anti-inflammatory drugs which control and regulate symptoms such as abdominal cramps, joint pain and headache. Antidepressants such as fluoxetine, paroxetine and sertraline can also be included in the regular therapy but it must be taken before actual symptoms begin. In premenstrual dysphoric disorder, gonadotropin-releasing hormone (GnRH) agonists such as leuprolide or goserelin can also be employed to regulate rapid fluctuations in the hormone levels.
Nutritional therapy such as vitamin B6, vitamin E, calcium and magnesium along with moderate exercise help in increasing success rate of treatment. Calcium carbonate can be recommended as first-line therapy for women with mild-to-moderate PMS whereas, selective serotonin reuptake inhibitors can be considered as first-line therapy for women with severe PMS complications.
Major drivers to the growth of premenstrual syndrome market includes increasing inclination of key players and government interventions towards developing novel therapeutics as a long term cure to this disease. Awareness and growing concern about premenstrual syndrome especially among women from developed economic countries have effectively contributed towards demand for PMS drugs and diagnostic tests. Till date there is no diagnostic device present to confirm PMS or PMDD yet two of the well-validated scales for the recording of premenstrual symptoms include the Calendar of Premenstrual Experiences (COPE) and the Prospective Record of the Severity of Menstruation (PRISM). Growing demand for hormone therapy based treatment across the globe has tremendously contributed towards increase in revenues and upliftment of PMS market.
Geographically, North America and Europe market are major contributors in terms of revenues and research activities. Availability of advanced diagnostic equipments and healthcare facilities has a major contribution towards growth and development of market in past few years. Rest of the World and Asia-Pacific market are among the most lucrative market for existing as well as new players in forthcoming years owing to large women population base and increasing incidences of lifestyle related disorders in past one decade. Government interventions and campaigns with respect to women health and well-being are effectively contributing towards increasing awareness about Premenstrual syndrome and other associated menstrual disorders in developing economic countries. Some of the pipelined drugs in the market include ProgestoMat, Cis-platinum, CDB-2914, PH80-PMD, Dutasteride and others.
Some of the key players operating in the Premenstrual Syndrome market include MetP Pharma AG, Umecrine Mood AB, DEKK-TEC, Inc., Pherin Pharmaceuticals, Inc. and others.
This research report analyzes this market on the basis of its market segments, major geographies, and current market trends. Geographies analyzed under this research report include
- North America
- Asia Pacific
- Rest of the World
This report provides comprehensive analysis of
- Market growth drivers
- Factors limiting market growth
- Current market trends
- Market structure
- Market projections for upcoming years
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter's five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed
value chain analysis.
Read More Report on Pharmaceutical Market:
About Transparency Market Research
Transparency Market Research (TMR) is a market intelligence company providing global business research reports and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers.
TMR's experienced team of analysts, researchers, and consultants use proprietary data sources along with various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information which is indispensable for businesses to sustain their competitive edge.
Inquiry Before Buying: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2922
Latest Press Release Reports: http://www.transparencymarketresearch.com/press-releases.htm
Latest Articles Reports: http://www.transparencymarketresearch.com/articles.htm
Mr. Nachiket Ghumare
90 State Street,
Albany NY - 12207